As part of a search for selective, mechanism-based covalent inhibitors of human pancreatic a-amylase we describe the chemoenzymatic synthesis of the disaccharide analog a-glucosyl epi-cyclophellitol, demonstrate its stoichiometric reaction with human pancreatic a-amylase and evaluate the time dependence of its inhibition. X-ray crystallographic analysis of the covalent derivative so formed confirms its reaction at the active site with formation of a covalent bond to the catalytic nucleophile D197. The structure illuminates the interactions with the active site and confirms OH4' on the nonreducing end sugar as a good site for attachment of fluorescent tags in generating probes for localization and quantitation of amylase in vivo.Keywords: activity-based probes; amylase; conduritol epoxide; GH13 structure; glycosyl enzyme; mechanism-based inhibition Digestion of starch in mammals starts with endocleavage of its a-1,4-glucosidic bonds by salivary and pancreatic a-amylases. This liberates oligosaccharides that are hydrolyzed further by a-glucosidases located on the gut wall, thereby delivering glucose to the bloodstream. Control of blood glucose levels can be achieved clinically by a-glucosidase inhibitors (AGI) such as acarbose and miglitol, which inhibit the gut wall enzymes [1,2]. However unpleasant side effects, in part associated with passage of the oligosaccharides to the lower gut, can limit patient compliance. An alternative strategy, which our laboratory has been exploring, is to employ specific inhibitors of the a-amylases that allow dietary oligosaccharides such as sucrose to be processed normally. This approach should minimize side effects while still reducing blood glucose levels. To that end, we have taken two approaches. High-throughput screening of natural product extracts is one approach, and has led us to the potent (K i = 8.1 nM) human pancreatic a-amylase (HPA) inhibitor montbretin A, which controls blood glucose in diabetic animals, and for which we have determined three-dimensional structures of its complex with HPA [3,4].The other approach has been through design of mechanism-based inhibitors that form covalent adducts with the HPA active site. While 2-deoxy-2-Abbreviations CP, cyclophellitol; ECP, epi-cyclophellitol; G-ECP, glucosyl epi-cyclophellitol; HPA, human pancreatic a-amylase; LaMalP, Lactobacillus acidophilus NCFM maltose phosphorylase.